- |||||||||| Yervoy (ipilimumab) / Ono Pharma, BMS
Biomarker, Trial completion, Enrollment change, Trial primary completion date, IO biomarker: Immunogenicity and Biomarker Analysis of Neoadjuvant Ipilimumab for Melanoma (clinicaltrials.gov) - Dec 7, 2017 P1, N=59, Completed, Recruiting --> Completed | N=39 --> 26 | Trial primary completion date: Feb 2018 --> Aug 2017 Active, not recruiting --> Completed | N=28 --> 59 | Trial primary completion date: Nov 2017 --> Jul 2013
- |||||||||| Trial completion, Trial initiation date, Trial primary completion date: Moletest Clinical Study in Scotland (clinicaltrials.gov) - Dec 4, 2017
P=N/A, N=1120, Completed, Trial primary completion date: Sep 2016 --> Dec 2015 Not yet recruiting --> Completed | Initiation date: Aug 2014 --> Mar 2015 | Trial primary completion date: Aug 2014 --> Oct 2016
- |||||||||| Samcyprone (diphenylcyclopropenone) / Phio Pharma
Trial completion, Enrollment change, IO biomarker: Treatment of Cutaneous Metastases With Diphenylcyclopropenone (DPCP) (clinicaltrials.gov) - Nov 29, 2017 P1, N=6, Completed, Not yet recruiting --> Completed | Initiation date: Aug 2014 --> Mar 2015 | Trial primary completion date: Aug 2014 --> Oct 2016 Active, not recruiting --> Completed | N=13 --> 6
- |||||||||| Trial withdrawal: A Vaccine Study for High Risk Cancers (clinicaltrials.gov) - Nov 24, 2017
P1, N=0, Withdrawn, N=30 --> 22 | Trial primary completion date: Feb 2014 --> Sep 2009 Terminated --> Withdrawn
- |||||||||| Imjudo (tremelimumab) / AstraZeneca, Pfizer
Trial completion, Enrollment change, Trial initiation date, Trial primary completion date, Metastases: Study of AntiCTLA4 in Patients With Unresectable or Metastatic Uveal Melanoma (clinicaltrials.gov) - Oct 27, 2017 P2, N=11, Completed, Trial primary completion date: Jul 2017 --> Nov 2017 Active, not recruiting --> Completed | N=32 --> 11 | Initiation date: Jan 2010 --> Aug 2009 | Trial primary completion date: Jan 2013 --> Aug 2017
- |||||||||| doxazosin mesylate / Generic mfg.
Trial primary completion date: PRESCRIPT: Phenoxybenzamine Versus Doxazosin in PCC Patients (clinicaltrials.gov) - Oct 26, 2017 P4, N=134, Recruiting, Active, not recruiting --> Completed | N=32 --> 11 | Initiation date: Jan 2010 --> Aug 2009 | Trial primary completion date: Jan 2013 --> Aug 2017 Trial primary completion date: May 2017 --> Dec 2017
- |||||||||| temozolomide / Generic mfg.
Enrollment change, Trial termination: FMISOPETSCS: FMISO-PET in Brain Tumors and SCS Effect (clinicaltrials.gov) - Oct 19, 2017 P2, N=6, Terminated, Phase classification: P2 --> P=N/A N=20 --> 6 | Recruiting --> Terminated; Isotope (FMISO) production is no longer available in our country.
- |||||||||| Azedra (iobenguane I 131) / Lantheus
Phase classification, Trial initiation date: N2007-01: Ultratrace (clinicaltrials.gov) - Oct 4, 2017 P2a, N=15, Completed, Active, not recruiting --> Completed | Trial primary completion date: Feb 2016 --> Mar 2015 Phase classification: P2 --> P2a | Initiation date: Mar 2008 --> Jun 2008
- |||||||||| NN1213 / Novo Nordisk
Enrollment change, Trial initiation date, Trial termination, Metastases: Antineoplaston Therapy in Treating Patients With Metastatic, Recurrent, or Refractory Primitive Neuroectodermal Tumors (clinicaltrials.gov) - Sep 29, 2017 P2, N=1, Terminated, Initiation date: Oct 2014 --> Apr 2014 N=40 --> 1 | Initiation date: Aug 1998 --> Dec 1996 | Active, not recruiting --> Terminated; slow accrual
- |||||||||| NN1213 / Novo Nordisk
Enrollment change, Trial initiation date, Trial termination, Metastases: Antineoplaston Therapy in Treating Patients With Metastatic, Recurrent, or Refractory Neuroblastoma (clinicaltrials.gov) - Sep 28, 2017 P2, N=3, Terminated, Active, not recruiting --> Completed N=40 --> 3 | Initiation date: Aug 1998 --> Dec 1996 | Active, not recruiting --> Terminated; slow accrual
- |||||||||| Inlyta (axitinib) / Pfizer
Trial primary completion date: A Study of Axitinib in Advanced Carcinoid Tumors (clinicaltrials.gov) - Sep 27, 2017 P2, N=30, Active, not recruiting, N=40 --> 3 | Initiation date: Aug 1998 --> Dec 1996 | Active, not recruiting --> Terminated; slow accrual Trial primary completion date: Jun 2017 --> Jan 2017
- |||||||||| Biomarker, Trial completion, Trial primary completion date, Metastases: Dabrafenib/Trametinib, BRAF or BRAF AND MEK Pre-op With BRAF and MEK Post-op, Phase IIB, Melanoma With Brain Mets,Biomarkers and Metabolites (clinicaltrials.gov) - Sep 26, 2017
P2b, N=30, Completed, Trial primary completion date: Jun 2017 --> Jan 2017 Recruiting --> Completed | Trial primary completion date: Dec 2018 --> Apr 2017
- |||||||||| ADU-623 / Novartis
Enrollment closed, Enrollment change: Phase I Study of Safety and Immunogenicity of ADU-623 (clinicaltrials.gov) - Sep 25, 2017 P1, N=11, Active, not recruiting, Recruiting --> Completed | Trial primary completion date: Dec 2018 --> Apr 2017 Recruiting --> Active, not recruiting | N=38 --> 11
- |||||||||| Avastin (bevacizumab) / Roche
Trial completion, Enrollment change, Trial primary completion date: Bevacizumab and Irinotecan in Treating Young Patients With Recurrent, Progressive, or Refractory Glioma, Medulloblastoma, Ependymoma, or Low Grade Glioma (clinicaltrials.gov) - Sep 19, 2017 P2, N=97, Completed, Recruiting --> Active, not recruiting | N=38 --> 11 Active, not recruiting --> Completed | N=140 --> 97 | Trial primary completion date: Dec 2010 --> Oct 2015
- |||||||||| rhIL-15 / National Cancer Institute
Trial completion, Enrollment change, IO biomarker, Metastases: Recombinant Interleukin-15 in Treating Patients With Advanced Melanoma, Kidney Cancer, Non-small Cell Lung Cancer, or Squamous Cell Head and Neck Cancer (clinicaltrials.gov) - Sep 15, 2017 P1, N=20, Completed, Active, not recruiting --> Completed Active, not recruiting --> Completed | N=30 --> 20
|